How does precision medicine relate to treating Alzheimer’s disease? Can you share more with us about the blood biomarker research at Johns Hopkins?   With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on Alzheimer’s disease, the amyloid hypothesis, disease modification, and breakthroughs in diagnosis and treatment.   Today, Dr. Andy Cutler interviews Dr. Kostas Lyketsos about the most current research on treatment for Alzheimer’s disease, including precision medicine and behavioral modifications.   Constantine (Kostas) Lyketsos, MD, MHS, FACLP, FACNP is an active clinician, teacher, and researcher, Dr. Lyketsos was the founding director of the Johns Hopkins Neuropsychiatry Service, which he led for over a decade. He developed one of the largest and most successful academic neuropsychiatry programs in the USA with special expertise in dementia and traumatic brain injury. Prior to taking leadership of the Johns Hopkins Bayview Department of  Psychiatry, he was co-director of the Johns Hopkins Division of Geriatric Psychiatry and Neuropsychiatry. He has held a joint faculty appointment at the Hopkins Bloomberg School of Public Health since 1994.  Let’s listen in to Part 3 of our theme: Alzheimer’s Disease: Beyond the Amyloid Hypothesis: Prevention, Management and Treatment of Alzheimer’s Disease   Subscribe to the NEI Podcast, so that you don’t miss another episode! 

What is Match Day? What types of resources does Inside the Match provide for match applicants? In this episode, psychiatry resident, Dr. Simone Bernstein addresses these questions and much more! Simone Bernstein is a fourth-year psychiatry resident at Washington University in St. Louis and Co-Founder of Inside the Match, a platform that provides free application and interview guidance to residency applicants as well as tips to be successful in residency. The platform has a website with 250+ blogs to help you prepare for the match and more than 120+ episodes on Spotify, Apple, and Google podcasts. Simone has spoken at conferences worldwide, is a Laughlin Fellow, Forbes 30 Under 30 Social Entrepreneur, was featured as one of Glamour Magazine’s Top 10 College Women, is an inductee in the Missouri Public Affairs Hall of Fame, and is also a Fulbright Scholar. Find Inside The Match on Instagram and Twitter @Inside_TheMatch. 

What sorts of imaging techniques are used to measure amyloid aggregates in the brain? What do we know about the relationship between symptoms of Alzheimer’s disease and amyloid levels that are detected through neuroimaging? With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on Alzheimer’s disease, the amyloid hypothesis, disease modification, and breakthroughs in diagnosis and treatment. Today, Dr. Andy Cutler interviews Dr. Lon Schneider on biomarkers for Alzheimer’s disease and treatments that target amyloid. Lon Schneider, MD, MS is Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California. He is director of the California Alzheimer's Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer's Disease Research Center (National Institutes of Health). In addition, he is principal investigator of the National Institute of Mental Health's CATIE program, a multicenter effectiveness trial of atypical antipsychotics in Alzheimer's disease. Let’s listen in to Part 2 of our theme: Biomarkers and Treatments that Target Amyloid Subscribe to the NEI Podcast, so that you don’t miss another episode!

What cultural perspectives may influence mental health stigma in the Middle East? What was your experience like creating the first transcranial magnetic stimulation (TMS) center in Kuwait? What advice do you have for clinicians who want to help reduce the stigma that surrounds mental health? In this episode, psychiatrist Dr. Mohammad Alsuwaidan address these questions and much more. Dr. Mohammad Alsuwaidan MD, MPH, FRCPC, DipABPN is an assistant professor of psychiatry at the University of Toronto in Canada. He is also the founder and clinical director of MindWell, a leading regional private mental health center based in Kuwait and the Chief Medical Officer of TMS NextGen a TMS training and operations management company based in Dubai. Dr. Alsuwaidan completed his psychiatry residency, mood & anxiety disorders fellowship and medical education fellowship at the University of Toronto. He also trained in mood disorders at the Stanford University bipolar clinic and the Tufts Medical Center mood disorders clinic. He completed a Masters of Public Health (MPH) at Johns Hopkins University. He is a Fellow of the Royal College of Physicians and Surgeons of Canada, a Diplomate of the American Board of Psychiatry and Neurology and is certified in public health by the National Board of Public Health Examiners. He was the host for the 2022 NEI Congress, and he is widely-sought internationally as a speaker, educator and anti-stigma advocate in mental health.

When it comes to Alzheimer’s disease, what is the amyloid cascade hypothesis? How has this theory impacted drug development for Alzheimer’s disease over the past three decades? With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on Alzheimer’s disease, the amyloid hypothesis, disease modification, and breakthroughs in diagnosis and treatment. Today, Dr. Andy Cutler interviews Dr. Stephen Stahl on the current state of Alzheimer’s disease and the amyloid controversy. Let’s listen in to Part 1 of our theme: Alzheimer’s Disease and the Amyloid Controversy Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, we invite Dr. Christine Moutier of the American Foundation for Suicide Prevention, along with Christopher Thomas and Martha Thomas of the Defensive Line so they could have a chance to address some of your unanswered questions from their presentation on suicide prevention at the 2022 NEI Congress titled “Reasons to Hope: Evidence-Based Actions for Suicide Prevention. Christine Moutier serves as the chief medical officer for the American Foundation for Suicide Prevention (AFSP) and knows the impact of suicide firsthand. After her own lived experience and losing physician colleagues to suicide, she dedicated herself to fighting this leading cause of death. For the past decade as CMO at AFSP, Dr. Moutier has been leading a nationwide movement fueled by science and grassroots. She has testified before Congress numerous times, presented at the White House and the National Academy of Sciences, and is a frequent expert contributor for major media outlets.   Martha co-founded The Defensive Line with Chris and her son, Solomon to honor her daughter, Ella, and to bring a message of hope and help to other at-risk young people. She is the roots of her family and believes and demonstrates fundamentally that connection is our greatest source of strength. She recently stepped out of the classroom to work full-time in her role as the Chief Education Officer for the organization. While she is no longer in the classroom, she is still teaching others important lifesaving skills. As a teacher and educator for 30 years, Martha brings a deep understanding of the profession to The Defensive Line. Martha resides in Coppell, Texas with her husband, Chris, and two rescue dogs Mickey and Rebel. She is a marathoner and devoted friend to many, as well as a huge fan of the New York Jets for whom her son, Solomon, plays as a defensive lineman. As a senior executive at Procter & Gamble, Frito-Lay, and Alberto Culver among others, Chris brought a drive for excellence to his work, earning recognition and industry awards including Salesperson of the Year and Supplier of the Year. He is a member of the Board of Directors of the American Foundation for Suicide Prevention, as well as Touched By Suicide (TBS) board member, AFSP Project 2025 board member, and College of Wooster Ad Hoc Alumni Trustee. Martha, Chris, and Solomon were recipients of the 2019 AFSP Lifesaver Award. During his 30-plus years in corporate management of consumer goods and products, both domestically and internationally. A gifted college athlete, Chris played an integral role in coaching and developing the athletic achievements of his children, Ella and Solomon. In addition to receiving the AFSP Lifesaver Award in 2019 with Solomon, Martha and Chris are active with suicide survivors organizations, have spoken at the 2022 Neuroscience Education Institute Congress, Texas Association of Gifted and Talented Conference, United Healthcare Suicide Prevention Town Hall and many others.

Why is measurement-based care so important to the overall treatment of schizophrenia? What are the most important reasons for using plasma antipsychotic levels when treating schizophrenia patients?   In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the importance of measuring plasma levels when administering antipsychotics.   With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on complex treatment-resistant psychotic disorders.  Episodes to be released under this theme include:  Part 1: Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings  Part 2: The Clozapine Handbook with Dr. Jonathan Meyer  Part 3: Don’t Guess! Measure: The Clinical Use of Antipsychotic Plasma Levels with Dr. Jonathan Meyer  Subscribe to the NEI Podcast, so that you don’t miss another episode! 

What did we learn about the relationship between PTSD and the gut microbiome this year? What are pherines? How can they reduce anxiety, according to research that was published this year? What other exciting news about psychopharmacology do you have to share with us? In this episode, Dr. Cutler addresses these questions and so much more about this past year in psychopharmacology. Dr. Andrew Cutler is the Chief Medical Officer (CEO) at the Neuroscience Education Institute (NEI). Dr. Cutler has deeply rooted knowledge in clinical experience, academic experience, and emerging science in psychiatry through clinical trials. He also worked closely with federal regulators and legislators to advocate for improved mental health care as part of the Clinton health care reform effort, leading to the Mental Health Parity Act of 1996. Among his notable leadership positions, Dr. Cutler is currently Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida, and has been the principal investigator on more than 400 psychiatric and medical clinical trials. Dr. Cutler received a BS in biology from Haverford College in Philadelphia, and then received his medical degree from the University of Virginia School of Medicine, where he was elected to Alpha Omega Alpha honor medical society. He completed his medical internship, internal medicine residency, and psychiatry residency at the University of Virginia, where he served as Chief Resident of Psychiatric Medicine. Dr. Cutler then served as Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He is board certified in internal medicine and psychiatry.

Why is clozapine underutilized, even though it’s a very effective antipsychotic for treatment-resistant schizophrenia? What led you to write The Clozapine Handbook? In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the use of clozapine in clinical practice.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings Part 2: The Clozapine Handbook with Dr. Jonathan Meyer Part 3: Don’t Guess! Measure: The Clinical Use of Antipsychotic Plasma Levels with Dr. Jonathan Meyer Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, Dr. Mary Kimmel answers your important questions from her presentation: No Woman, No Cry: Advancements in the Diagnosis and Treatment of Postpartum Depression.